US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Merck & Co., Inc.

MRKNYSE

111.07

USD
-1.23
(-1.10%)
Market Closed
21.63P/E
13Forward P/E
0.90P/E to S&P500
281.833BMarket CAP
2.49%Div Yield

Merck & Co., Inc.

NYSE:MRK

RECENT
PRICE

111.07

P/E
RATIO

21.63

(PEG:1.96)

P/E RATIO
RELATIVE
TO S&P

0.90

DIV
YLD

3.66%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

- - Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 05/23:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

TTM

Fiscal year

11.15

1.51

2.76

1.52

11.17

3.66

2.47

1.54

13.01

6.12

0.92

1.65

14.86

0.28

2.95

1.57

15.80

2.06

3.51

1.58

15.62

2.04

2.67

1.73

15.04

1.50

3.45

1.80

14.88

4.20

1.95

1.85

14.20

1.60

4.00

1.84

14.48

1.43

3.19

1.86

14.88

0.89

1.69

1.92

16.31

2.40

3.20

1.99

18.45

3.88

3.93

2.24

18.97

2.79

2.20

2.46

19.25

5.16

3.82

2.61

23.41

5.73

5.81

2.77

30.46

5.14

5.93

3.75

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.47

8.38

0.61

8.78

0.69

28.01

0.54

17.57

0.57

17.93

0.65

17.52

0.53

17.00

0.82

17.14

0.46

16.06

0.59

14.58

0.70

12.73

1.01

10.30

1.37

10.20

1.85

10.01

1.76

15.09

1.73

18.16

2.32

23.75

CAPEX per share

Book Value per share

2,171

2,136

2,109

3,095

3,041

3,027

2,928

2,838

2,781

2,749

2,697

2,593

2,539

2,530

2,530

2,532

1,900

Comm.Shares outs.(m)

33.6

1.9

3.0%

10.0

0.5

4.2%

4.8

0.1

5.6%

129.7

6.3

4.3%

16.6

1.0

4.6%

20.3

1.4

4.2%

30.8

1.8

3.9%

13.6

0.7

3.2%

35.3

1.8

3.3%

40.0

1.8

3.3%

69.7

3.0

3.1%

26.7

1.1

3.1%

21.1

0.9

2.7%

28.8

0.8

3.0%

15.0

0.5

3.4%

15.7

0.7

3.1%

21.6

0.9

3.7%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/3/23 | Q1)

Total liabilities
$52,124 m.

Total assets
$98,958 m.

Long-term debt
$28,074 m.

Cash and equiv.
$9,707 m.

Goodwill $21,209 m.

Retained earnings $62,039 m.

Common stock - -

Market Capitalisation
$281,833 m. (as of 28/5/23)

47,267

20.9%

44,033

17.4%

42,237

15.8%

39,498

19.1%

39,807

15.1%

40,122

18.2%

42,294

21.1%

46,840

26.1%

47,994

17.7%

48,704

27.1%

59,283

30.8%

57,869

24.2%

Revenue (m)

Operating margin

6,978

6,168

6,988

4,404

6,691

11,920

6,375

4,442

5,441

3,920

4,637

2,394

4,519

6,220

3,652

9,843

3,625

7,067

3,214

13,049

- -

14,519

2,789

13,030

Depreciation (m)

Net profit (m)

27.9%

13.0%

18.5%

10.0%

30.9%

28.2%

17.4%

11.2%

15.4%

9.8%

62.9%

6.0%

28.8%

14.7%

14.7%

21.0%

19.4%

14.7%

11.0%

26.8%

11.7%

24.5%

14.5%

22.5%

Income tax rate

Net profit margin

16,509

16,254

53,020

17,817

20,539

49,765

14,407

18,699

48,647

10,561

23,929

44,676

13,410

24,274

40,088

6,152

21,353

34,336

3,669

19,806

26,701

5,263

22,736

25,907

437

25,360

25,317

6,394

30,690

38,184

11,483

28,745

45,991

10,271

28,074

46,834

Working capital (m)

Long-term debt (m)

Equity (m)

7.9%

9.0%

11.6%

6.0%

6.0%

8.8%

15.6%

18.3%

24.5%

6.1%

6.0%

9.9%

5.8%

5.6%

9.8%

3.9%

8.3%

7.0%

11.2%

11.5%

23.3%

17.1%

14.7%

38.0%

12.1%

10.5%

27.9%

16.7%

14.6%

34.2%

17.1%

15.1%

31.6%

15.8%

14.2%

27.8%

ROIC

Return on capital

Return on equity

Working Capital

2020

2021

2022

Cash assets

8,847

8,881

13,479

Receivables

7,851

9,230

9,450

Inventory

6,310

5,953

5,911

Other

4,756

6,987

7,169

Current assets

27,764

30,266

35,722

Acc. Payable

4,594

4,609

4,264

Debt due

6,431

2,412

1,946

Other

16,302

16,851

18,029

Current liab.

27,327

23,872

24,239

15.1%

97.0%

(19.8)%

116.7%

56.0%

233.6%

(15.2)%

83.5%

(30.7)%

97.7%

(115.8)%

201.4%

16.8%

171.7%

42.1%

105.1%

12.1%

134.6%

49.3%

77.1%

51.7%

47.7%

45.4%

64.3%

Plowback ratio

Div.&Repurch. to FCF

Merck & Co., Inc. (US) started trading on June 6, 1946 (cik: 0000310158), operates in the Healthcare sector (Drug Manufacturers—General industry), has 67,000 full-time employees, and is led by Mr. Robert M. Davis J.D.. Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

9.10%

3.65%

Cash flow

25.39%

18.92%

Earnings

31.49%

38.11%

Dividends

7.92%

3.30%

Book value

16.50%

0.97%

Insider trading

Type

Shares

Date

Mizell Steven

Exempt

13,000

05/03/23

Mizell Steven

Exempt

15,000

05/03/23

Mizell Steven

Exempt

12,000

05/03/23

Mizell Steven

Sale

13,000

05/03/23

Mizell Steven

Sale

15,000

05/03/23

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2021

12,080

11,402

13,154

13,521

50,157

2022

15,901

14,593

14,959

13,830

59,283

2023

14,487

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2021

1.26

0.61

1.81

1.51

5.18

2022

1.70

1.56

1.28

1.19

5.73

2023

Infinity

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2021

0.65

0.66

0.65

0.65

2.61

2022

0.69

0.70

0.69

0.69

2.77

2023

Infinity

- -

- -

- -

- -

04/26/2023

Merck Struggles to Expand Its Cancer-Drug Juggernaut

The Wall Street Journal - Read more...

04/18/2023

How to Tell Biotech’s Likely Winners From Losers

The Wall Street Journal - Read more...

04/16/2023

Merck to Buy Prometheus Biosciences

The Wall Street Journal - Read more...

03/06/2023

Alternatives to Popular Cholesterol Drug Cut Heart-Attack Risk

The Wall Street Journal - Read more...

02/09/2023

Pfizer, Novartis, Merck Executives Say They Are Hunting for Deals Again

The Wall Street Journal - Read more...

02/08/2023

Insurers Say Cyberattack That Hit Merck Was Warlike Act, Not Covered

The Wall Street Journal - Read more...

12/13/2022

Moderna’s mRNA Cancer Vaccine Shows Promise in Preliminary Study

The Wall Street Journal - Read more...

11/21/2022

Merck Strikes $1.35 Billion Deal for Bone-Marrow Disease Drug Developer

The Wall Street Journal - Read more...

10/31/2022

Drugmakers Fight Over Lucrative Pneumonia Vaccines

The Wall Street Journal - Read more...

10/27/2022

Merck Lifts Outlook After Quarterly Sales Rise 14%

The Wall Street Journal - Read more...

10/27/2022

Merck Shuffles Board Chairmen

The Wall Street Journal - Read more...

10/11/2022

Merck’s Patent Cliff Doesn’t Look So Frightening Anymore

The Wall Street Journal - Read more...

07/26/2022

Drugmakers Hope New Heart Drugs Boost Sales, Revive Market

The Wall Street Journal - Read more...

07/15/2022

Merck Deal for Seagen Seen as Unlikely by Earnings Release

The Wall Street Journal - Read more...

07/07/2022

Merck Is in Advanced Talks to Buy Cancer Biotech Seagen

The Wall Street Journal - Read more...

07/03/2022

Merck’s Covid-19 Pill Prescribed Often in Some Countries Despite Low Efficacy

The Wall Street Journal - Read more...

06/23/2022

Merck Pushes Forward With Potential Deal for Seagen

The Wall Street Journal - Read more...

06/22/2022

Merck Acquisition Would Test Emboldened Regulators

The Wall Street Journal - Read more...

06/18/2022

Merck Eyes Purchase of Biotech Seagen

The Wall Street Journal - Read more...

05/24/2022

Covid-19 Vaccine and Drug Sales, Once Booming, Plateau

The Wall Street Journal - Read more...

03/14/2022

Merck’s Covid-19 Pill Heavily Used So Far Despite Concerns

The Wall Street Journal - Read more...

02/03/2022

Merck, Eli Lilly Covid-19 Treatments Power Quarterly Sales Gains

The Wall Street Journal - Read more...

02/03/2022

Meta, Amazon, Snap, Pinterest: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

01/28/2022

Merck’s Covid-19 Pill Shows Promise Against Omicron

The Wall Street Journal - Read more...

01/07/2022

GameStop, AMC, DraftKings, Starbucks: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

12/23/2021

FDA Authorizes Merck’s Covid-19 Pill for At-Home Treatment

The Wall Street Journal - Read more...

12/01/2021

Salesforce, Snowflake, Zscaler, Box: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/30/2021

Omicron Variant Sends Policy Makers Scrambling as Science Lags Behind

The Wall Street Journal - Read more...

11/30/2021

Peloton, Moderna, Marriott, Pfizer: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/29/2021

Moderna, Coinbase, Occidental, Royal Caribbean: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/26/2021

Merck’s Covid-19 Pill Was 30% Effective in Final Analysis

The Wall Street Journal - Read more...

11/08/2021

Tesla, Coinbase, Merck: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

11/04/2021

Tesla, Moderna, Zillow, Qualcomm, Qorvo: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

11/04/2021

Merck Covid-19 Pill Cleared for Use in U.K., Its First Authorization

The Wall Street Journal - Read more...

10/28/2021

Shiba Inu Coin, Tesla, Ford, Nokia: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

10/27/2021

Promising Covid-19 Pill Licensed to Nonprofit to Increase Global Supply

The Wall Street Journal - Read more...

10/12/2021

Airbnb, Merck, High Tide, Square: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

10/11/2021

Merck Asks FDA to Authorize Promising Covid-19 Pill

The Wall Street Journal - Read more...

10/11/2021

Marathon Digital, Occidental, Southwest: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

10/04/2021

Tesla, Merck, Moderna: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

10/01/2021

Merck Pill Intended to Treat Covid-19 Succeeds in Key Study

The Wall Street Journal - Read more...

10/01/2021

AMC, Bitcoin, Lordstown, Merck: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

09/30/2021

Merck to Buy Acceleron Pharma for $11.5 Billion

The Wall Street Journal - Read more...

09/30/2021

Virgin Galactic, Camber Energy, Bed Bath & Beyond, Jefferies: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

09/28/2021

Facebook, Ford, Acceleron Pharma: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

09/27/2021

Merck Nears Deal to Acquire Acceleron Pharma

The Wall Street Journal - Read more...

07/25/2021

Race for Covid-19 Pill Heats Up

The Wall Street Journal - Read more...